Online healthcare company Teladoc Health’s   shares fell Thursday as several analysts lowered their share-price targets – following lower-than-expected quarterly earnings.

Teladoc reported a loss of -$1.31 a share, steeper than the -40 cents loss expected by analysts.It is also wider than the year-ago quarter’s  -40 cents per share.

Evercore ISI’s Elizabeth Anderson slashed her price target to $185 from $195 and kept her in-line rating.

GoodRx  soared in its debut trading Wednesday on the Nasdaq. The company, a digital prescription price comparison and coupon provider, saw its stock recently traded at $48.45, up +46.81% from its initial public offering price of $33, which in turn was well above the $24 to $28 range set by the underwriters. Inn the six months ended June 30, GoodRx’s net income totaled  $54.7 million, up from $31.2 million a year earlier.Revenue of $256.7 million was higher than $173.2 million a year earlier. Co-founders and CEOs Doug Hirsch and Trevor Bezdek wrote in the prospectus that “so far, we’ve saved Americans an estimated $20 billion on prescriptions and medical services.

Teladoc Health (NYSE: TDOC) is somewhat of a hybrid company, caught between technology and healthcare.Regardless of what the company does, the stock has been in a downward trend for the last seven months.  The decline started last October and it saw the stock drop from over $85 a share to $42.50 in December.